Reuters logo
BRIEF-Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio
October 10, 2017 / 10:51 AM / in a month

BRIEF-Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio

Oct 10 (Reuters) - Eli Lilly And Co

* Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio™ (abemaciclib) in kras-mutated, advanced non-small cell lung cancer

* Eli Lilly And Co - ‍lilly will submit data for presentation at a medical meeting in 2018​

* Eli Lilly And Co -Phase 3 JUNIPER study evaluating Verzenio​ ‍did not meet its primary endpoint of overall survival

* Eli Lilly - ‍however, analysis of secondary study endpoints of both progression-free survival and overall response rate showed evidence of monotherapy activity in abemaciclib arm​

* Eli Lilly - ‍control arm in Phase 3 JUNIPER study for Verzenio​ showed higher overall survival rate than expected based on historical data in setting Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below